Wegovy and Zepbound Medicare Coverage in 2026: Medicare Advantage vs Original Medicare Part D, the New Bridge Program, and the MSP Benefit That Could Save You $2,220 Per Year
Wegovy and Zepbound Medicare Coverage in 2026: Medicare Advantage vs Original Medicare Part D, the New Bridge Program, and the MSP Benefit That Could Save You $2,220 Per Year
Your doctor just recommended Wegovy or Zepbound. You're on Medicare. You looked up the price: $1,349 per month for Wegovy. $1,059–$1,349 per month for Zepbound depending on dose. That's up to $16,188 per year — before a single copay or deductible elsewhere in your coverage.
Here's the actual decision you're facing right now: does your Medicare plan cover GLP-1 weight loss drugs at all, and if not, which plan type would? The answer depends on three variables most beneficiaries don't know to check simultaneously — your plan's formulary, your income relative to MSP thresholds, and whether a new bridge program announced in May 2026 applies to your drug and diagnosis. Let's work through the real numbers.
Why Traditional Medicare Part D Pays $0 Toward Wegovy and Zepbound
This isn't a quirk of your specific plan. Traditional Part D does not cover GLP-1 drugs when the sole qualifying diagnosis is obesity. The exclusion dates to 2003, when Congress prohibited Medicare from covering drugs prescribed primarily for weight loss. That statutory language hasn't changed.
The exception that trips people up: if you also have Type 2 diabetes, semaglutide branded as Ozempic (prescribed for T2D) may be covered under your Part D formulary. But Wegovy (semaglutide for obesity) and Zepbound (tirzepatide for obesity) are categorized separately in CMS formulary data — and that distinction is the difference between a $2,000 annual cap and a $16,188 annual bill.
If your only qualifying ICD-10 code is E66.x (obesity), your Part D plan — regardless of how comprehensive it is otherwise — pays zero. Medigap Plan G covers none of it either, because Medigap only pays Medicare-approved cost-sharing. No formulary coverage means no Medigap protection.
We've covered the T2D vs. obesity classification distinction in detail in our post on Ozempic vs. Wegovy on Medicare Part D in 2026 — including how formulary tier placement can shift your cost by thousands even when coverage exists.
The New Bridge Program: What KFF Health News Reported in May 2026
KFF Health News reported in May 2026 that it may soon get significantly easier for Medicare beneficiaries to access GLP-1 drugs for weight loss through a new pathway called Foundayo — a bridge program designed to provide discounted access while the broader policy and statutory questions work through Congress and CMS.
What the bridge program doesn't change: your underlying plan structure still determines how any cost-sharing is handled, and whether your prescribing physician's documentation meets the program's qualifying criteria. The bridge program is a potential floor — it doesn't replace the need to compare your actual plan options for 2026.
What it does change: for beneficiaries currently paying full retail because their plan covers nothing, even a partial discount on a $1,349/month drug is material. A 50% reduction, for example, would cut annual out-of-pocket from $16,188 to $8,094 — still significant, but a different comparison point against plans that cover GLP-1s with the IRA's $2,000 annual cap.
This is the kind of formulary-level analysis Toravine runs for you — because the gap between "covered at Tier 4 with the $2,000 IRA cap" and "not on formulary" is $14,000 per year, and that gap lives entirely in your plan selection.
The 10-Year Cost Comparison by Plan Type: Four Real Scenarios
Based on Toravine's analysis of 1,236 rows of CMS Medicare plan premium data and 3,570 rows of Medigap rate data across states, here's what the numbers look like for a 65-year-old Medicare beneficiary who needs Wegovy for obesity without a T2D diagnosis, and is otherwise healthy.
| Scenario | Plan Structure | Annual Premium Cost | Annual GLP-1 OOP | Annual Total | 10-Year Total |
|---|---|---|---|---|---|
| A | Original Medicare + Standard Part D | $2,772 | $16,188 (not covered) | $18,960 | $189,600 |
| B | MA HMO, $0 premium (no GLP-1 benefit) | $2,220 (Part B only) | $16,188 (not covered) | $18,408 | $184,080 |
| C | MA HMO with GLP-1 obesity benefit, Tier 4 | $2,520 (Part B + $25/mo MA) | $2,000 (IRA cap) | $4,520 | $45,200 |
| D | Medigap Plan G + Part D (avg $150/mo, per Toravine medigap_rates dataset) | $6,372 | $16,188 (not covered) | $22,560 | $225,600 |
(10-year projections assume 3% annual premium growth and stable formulary status. GLP-1 costs in Scenario A, B, D assume no bridge program discount.)
The 10-year gap between Scenario C and Scenario A is $144,400. That's not a rounding error — that's what the formulary decision is actually worth over a decade.
And here's what makes Scenario D painful to look at: Medigap Plan G is an excellent plan for hospitalization and outpatient cost-sharing protection. If you're managing multiple chronic conditions, it may still be the right call overall. But it provides exactly zero additional protection for uncovered GLP-1 drugs. You can have the best Medigap policy available and still face $16,000/year in out-of-pocket drug costs if Wegovy isn't on your formulary.
For more on the Medigap Plan G vs. Medicare Advantage trade-off — particularly for beneficiaries managing chronic conditions — see our post on Medicare Advantage HMO vs. Original Medicare + Medigap Plan G: the 10-year cost comparison for beneficiaries with chronic conditions.
The IRA's $2,000 Cap Only Protects You on Drugs Your Plan Actually Covers
The Inflation Reduction Act's $2,000 Part D out-of-pocket cap — now fully in effect for 2025 and 2026 — is genuinely transformative for beneficiaries on expensive specialty medications. But it only applies to drugs your plan covers on formulary.
A $0 formulary benefit gives you a $0 cap benefit.
This is the framing that matters: if a Medicare Advantage plan in your county covers Wegovy or Zepbound for obesity on its formulary at Tier 4 (specialty tier), the IRA cap kicks in. You pay cost-sharing until you hit $2,000, then $0 for the rest of the year. Spread across 12 months, that's a maximum of $167/month in drug costs — compared to $1,349/month with no coverage.
If your current plan doesn't cover GLP-1s for obesity, the IRA cap is irrelevant for this drug. You are paying full list price every month, with no ceiling.
The MSP Angle: 6 Million Beneficiaries Missing $2,220/Year in Free Premium Coverage
Before you run any plan comparison for GLP-1 coverage, there's a prior question worth answering: do you qualify for a Medicare Savings Program?
A May 2026 analysis by the Medicare Rights Center, citing an AARP Public Policy Institute report, found that up to 6 million Medicare beneficiaries are eligible for MSPs but not enrolled. The report also found that the asset tests used to screen MSP eligibility — typically $9,660 for individuals and $14,470 for couples — create bureaucratic costs without generating program savings. In other words, the administrative overhead of running asset screens costs more than the money saved by denying coverage.
Here's why MSP enrollment matters directly to the GLP-1 coverage question:
| MSP Level | Income Threshold (2026 approx.) | What It Pays |
|---|---|---|
| QMB (Qualified Medicare Beneficiary) | ≤ 100% FPL (~$15,060/individual) | Part A + B premiums, deductibles, coinsurance, copays |
| SLMB (Specified Low-Income Medicare Beneficiary) | 100–120% FPL | Part B premium ($185/month = $2,220/year) |
| QI (Qualifying Individual) | 120–135% FPL | Part B premium |
If you qualify for SLMB and aren't enrolled, you're paying $185/month — $2,220/year — for a benefit the program should be covering. That $2,220 is money that could partially offset GLP-1 costs, or fund a Medicare Advantage plan with a GLP-1 benefit.
If you qualify for QMB — the most comprehensive MSP tier — you can't be charged cost-sharing on Medicare-covered services at all. That completely changes the MA vs. Medigap calculation, because a $0 premium MA plan with QMB protections can produce lower net annual costs than Medigap Plan G for many beneficiaries in this income range.
Toravine's census_acs_medicare dataset (6,287 rows from the 2022 ACS 5-year estimates) shows meaningful shares of Medicare beneficiaries in states without simplified MSP asset test rules are likely in this unclaimed-benefit zone — particularly in states that haven't modernized their eligibility thresholds.
The Irreversible Risk: Switching Plans for GLP-1 Coverage Locks In a Medigap Underwriting Problem
If you currently have Original Medicare + Medigap Plan G and you want to switch to a Medicare Advantage plan specifically because it covers GLP-1 drugs — you can do that during Annual Enrollment (October 15 – December 7, 2026).
But here's the catch: if you later want to switch back to Medigap, you'll face medical underwriting in most states. Being on a GLP-1 drug for obesity may be treated as a pre-existing condition by Medigap insurers in states without guaranteed issue protections. Premiums can be significantly higher, or coverage can be denied outright.
In 2026, only a small number of states — California, Massachusetts, New York, Connecticut, and a few others — provide guaranteed issue rights for Medigap at any time after your initial enrollment window. In the remaining states, if you switch to MA for the GLP-1 benefit and your health changes, returning to comprehensive Medigap coverage may not be available at a reasonable price.
This isn't a reason to avoid the switch if the numbers support it. It's a reason to make the decision with full information about the one-way door you may be walking through. Our post on Medigap Plan G premium increases and the enrollment windows that let you switch without underwriting covers the specific state rules and timing in detail.
The 3 Questions to Answer Before October Open Enrollment
1. Does your current plan cover GLP-1 for your specific diagnosis? Search your plan's formulary for semaglutide (Wegovy) and tirzepatide (Zepbound) by brand name. Check the tier, prior authorization requirements, and any step therapy requirements. Many MA plans require documented failure on other treatments before approving GLP-1s.
2. Does any Medicare Advantage plan in your county cover GLP-1 for obesity? This requires a plan-by-plan formulary comparison — Medicare Plan Finder doesn't filter by GLP-1 obesity coverage. You need to check each plan's Evidence of Coverage document, or use a tool that does it for you.
3. Do you qualify for an MSP that would free up income or eliminate cost-sharing? Check MSP eligibility before comparing plans. If you're QMB-eligible, your cost-sharing picture changes fundamentally — and the best plan for a QMB-eligible beneficiary may look very different from the best plan without that protection.
The Bottom Line
The difference between having GLP-1 formulary coverage and not having it — on Medicare, in 2026 — is more than $14,000 per year. Over 10 years, that compounds to a six-figure gap. The bridge program announced in May 2026 may narrow that gap for some beneficiaries, but it doesn't eliminate the underlying plan selection question.
Your ZIP code, your diagnosis documentation, your income, and your current plan structure all feed into which option actually costs you less. Before the next Annual Enrollment Period opens in October, compare every Medicare Advantage plan available in your county against your actual drug regimen.
Toravine runs that comparison for you — including GLP-1 formulary status, prior authorization requirements, MSP eligibility screening, and 10-year cost projections specific to your health profile — so you don't have to build the spreadsheet yourself.
Sources
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know — KFF Medicare
- Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
- Gavin Newsom, Early Champion of Single-Payer, Moderates in the Face of Fiscal Limits — KFF Medicare
- Study Finds MSP Asset Tests Create Bureaucratic Costs Without Program Savings — Medicare Rights Center
- GLP-1s driving healthcare cost hikes, employers say — Healthcare Dive